Intravenous iron sucrose versus oral iron ferrous sulfate for antenatal and postpartum iron deficiency anemia: a randomized trial

2012 ◽  
Vol 26 (7) ◽  
pp. 654-659 ◽  
Author(s):  
Bernd Froessler ◽  
Carmel Cocchiaro ◽  
Khaschayar Saadat-Gilani ◽  
Nicolette Hodyl ◽  
Gustaaf Dekker
Author(s):  
Satish Kumar

Introduction: Anemia is the commonest major contributing factor in maternal mortality and morbidity in developing countries and according to World Health Organization (WHO) criteria, it contributes to 20% of maternal deaths. Anemia in pregnancy defined as hemoglobin level <11 gm/dl (7.45 mmol/L) and hematocrit less than 33% (WHO). Aim: To compare the efficacy of oral iron ferrous sulphate therapy with intravenous iron sucrose therapy in the treatment of iron deficiency anemia during postpartum period. Material & Methods: This was a prospective randomized comparative clinical trial single center study conducted on 200 postpartum women aged >18 years (after normal delivery or LSCS) within 10 days of delivery with Hb level more or equal to 6 gm/dl but less than 10 gm/dl were included in the study. This was a one year study conducted during 1st December 2018 to 30th November 2019. Results : There was a significant increase in the hemoglobin level in both the groups i.e. in IV iron group, from 8.26 ±1.03gm/dl on day 1 to 11.62±0.94gm/dl on day 45 as compared to oral iron group, from 8.24±1.09gm/dl on day 1 to 11.07±1.14gm/dl on day 45; and serum ferritin level from 41.69±40.45ng/ml on day 1 to 77.34±41.60ng/ml on day 45 in IV iron group as compared to the oral iron group from 22.20±8.82ng/ml on day 1 to 31.72±9.72 ng/ml on day 45. So, there was a rapid increase in both hemoglobin and serum ferritin levels in IV iron group as compared to the oral iron group. Conclusion: Intravenous iron sucrose administration increases the hemoglobin level and serum ferritin more rapidly in compare to the oral intake of ferrous sulphate in women with iron deficiency anemia in postpartum women in our study. Keywords: Iron deficiency anemia, Intravenous iron sucrose, Serum ferritin, Maternal mortality.


Author(s):  
Muzafar Naik ◽  
Tariq Bhat ◽  
Ummer Jalalie ◽  
Arif Bhat ◽  
Mir Waseem ◽  
...  

Background: Low dose (200 mg) extended Intravenous iron sucrose remains the most common treatment option in patients who are intolerant to oral iron therapy in patients with Iron deficiency anemia (IDA). The objective of this study was to evaluate the efficacy and safety of high dose accelerated intravenous iron sucrose (IS) in the treatment of adults with iron deficiency anemiaMethods: One hundred adult patients with iron deficiency anemia, who had intolerance or showed no effect with oral iron therapy, received daily doses of 500 mg of intravenous iron sucrose until the hemoglobin level was corrected or until receiving the total dose of intravenous iron calculated for each patient.Results: The mean and median Hb (g/dL) 6.47±1.656 and 6.6 (2) at baseline, 9.61±1.629 and 9.6 (2) at 2 weeks of treatment, 11.85±1.277 and 12 (1) at 4 weeks of treatment respectively. The mean rise of Hb was 3.13±1.41 and 5.37±1.50 after 2 and 4 weeks of treatment respectively (p<0.000). A total of 303 intravenous infusions of iron sucrose were administered and iron sucrose was generally well tolerated with twenty-six patients developing mild and one patient developing moderate adverse drug reactions. There was no serious adverse event recorded.Conclusions: Accelerated high dose intravenous iron sucrose is a safe and cost effective option minimizing frequent hospital visits in the treatment of adults with iron deficiency anemia who are intolerant or lack satisfactory response to oral iron therapy.


2020 ◽  
Vol 33 (1) ◽  
pp. 40-44
Author(s):  
Shabera Arzoo ◽  
Shereen Yousof ◽  
Jahanara Rahman ◽  
Sameena Chowdhury

Introduction: Injectable iron sucrose and oral ferrous sulfate both are used for the correctionof anaemia in second and third trimester of pregnancy. But injectable iron is supposed to bemore effective than oral iron, as it needs less time for correction of anaemia and efficacy ismore. Oral iron is cost effective but more time consuming.The objective of the study was to compare the safety of intravenous iron sucrose complex inthe treatment of iron deficiency anemia in third trimester of pregnancy. To compare theefficacy of intravenous iron with oral iron. Method: A randomised controlled trial was conducted in which pregnant women with irondeficiency were sequentially selected from the pregnant women attended antenatal clinic ofOPD of Institute of Child and Maternal Health (ICMH) and assigned either to injectable or tooral ferrous sulfate by random number table. Each study patient was given the total calculatedamount of injectable iron sucrose {Hb deficit (gm/l) × body weight (kg) × 0.24+ storage ironmg } in divided dose 200 mg in 200 ml normal saline intravenously over 1 hour everyalternate day . Each patient of the control group was given ferrous sulfate 200mg orally threetimes a day for 4 weeks. Pregnant women follow up at 4 weeks and 8 weeks after gettreatment by oral and injectable iron. During follow up monitored for adverse effects, clinicaland laboratory response and haemoglobin percentage were observed. Result: There were 75 patients in injectable group and 75 patients in oral group. Injectablegroup achieved a significantly higher Hb level (11.49 ± 0.39) than oral group Hb level (10.39± 0.75) after 8 weeks of treatment. Injectable group showed no major side effects, only twopatient had complains .One patient complain of epigastic pain and one patient complain oftachycardia while in oral group complain of nausea and vomiting, epigastic pain, constipation,allergic reaction was found in 42.0%, 39.3%,35.7% and 3.6% respectively. Conclusion: Iron sucrose complex appears to be a safe and effective in the treatment ofiron deficiency anemia. Bangladesh J Obstet Gynaecol, 2018; Vol. 33(1) : 40-44


2014 ◽  
Vol 94 (3) ◽  
pp. 523-525 ◽  
Author(s):  
Qingquan Shi ◽  
Jinhong Li ◽  
Qiang Yao ◽  
Chen Mi ◽  
Jing Yang ◽  
...  

Author(s):  
Vidya A. Thobbi ◽  
Zeba Naz M. Bijapur

Background: Iron deficiency anemia is the most common form of anemia and nutritional disorder worldwide. Oral iron therapy and blood transfusion has many drawbacks like noncompliance and risk of transmittable infections and transfusion reaction. The modern alternative therapy is treatment with intravenous iron. Present study compares the efficacy, safety and tolerability between intravenous iron sucrose and oral iron in iron deficiency anemia during 20-36 weeks of pregnancy.Methods: It was a randomized controlled study between December 2017 to September 2019. 200 patients attending antenatal OPD in Al Ameen Medical College, with haemoglobin levels between 7-9.9 gm/dl and serum ferritin of <15 ng/ml were enrolled. In intravenous group, 200 mg iron sucrose in 100ml normal saline was infused alternate day till the required dose was met. The oral group received 200 mg of oral iron ascorbate along with folic acid 1.5 mg per day for 6 weeks.  Treatment efficacy was assessed by Hb and serum ferritin after 3 and 6 weeks.Results: Out of 200 patients, an increase in Hb was observed in both groups, rising from 9.7 g/dl to 10.3 g/dl and 10.9 g/dl after 3 weeks and 6 weeks respectively in oral group and from 8.6 g/dl to 9.8 g/dl and 10.8 g/dl after 3 weeks and 6 weeks respectively in intravenous group. Similar results were seen in ferritin levels. Rise in Hb and ferritin levels were greater in intravenous group than in oral group.Conclusions: Intravenous iron sucrose appears to be a better treatment option in comparison with oral iron, without serious side effects, better compliance and improved efficacy in correction of anaemia of pregnancy.


Sign in / Sign up

Export Citation Format

Share Document